Top Image
Advanced Centre for Treatment Research & Education in Cancer
Facebook Twitter Gmail
Banner Image
Science Sparks @ ACTREC
Date Image 11th July 2022 Vol. No. 11; Issue No. 534

1. Behel V,Noronha V, Patil V, Menon N, Chandrani P, Kumar R, Rastogi S, Mahajan A, Chougule A, Dutt A, Prabhash K (2022). Molecular tumor board–guided treatment of non–small cell lung cancer with dual driver (ALK and EGFR) alterations. Cancer Research, Statistics and Treatment. 5(2): 337-341.

2. Mahajan A, Agarwal U, Patil V, Patil V, Vaish R, Noronha V,D'Cruz A, Chaturvedi P, Ghosh Laskar S, Sable N, Janu A, Shukla S, Patil A, Menon M, Rane S, Mittal N, Joshi A, Menon N, Prabhash K (2022). Proposed sub- compartmentalisation of high infratemporal fossa involvement in gingivobuccal cancers and its impact on clinical outcome and AJCC 8th edition. A narrative review. Cancer Research, Statistics Treatment. 5(2): 293-300.

3. Gattani S, Ramaswamy A, Noronha V, Castelino R, Kumar S, Rao A, Dhekle R, Krishnamurthy J, Kannan S, Gota V, Banavali S, Badwe R, Prabhash K (2022). ECOG performance status as a representative assessment of deficits in older Indian patients with cancer – A cross‑sectional analysis from a large cohort study. Cancer Research, Statistics and Treatment. 5(2): 280-286.

4. Moiyadi AV (2022). Neuropsychologists and their role in developing an awake craniotomy program. Neurology India. 70:1291-1292.

5. Behel V, Noronha V, Choughule A, Shetty O, Chandrani P, Kapoor A, Bondili SK, Bajpai J, Kumar R, Pai T, Bal M, Gurav M, Bapat P, Mittal N, Menon S, Patil V, Menon N, Dutt A, Prabhash K (2022). Impact of molecular tumor bard on the clinical management of patients With cancer. JCO Global Oncology.

6. Tibdewal A, Pathak R, Kumar A, Anand S, Ghosh Laskar S, Sarin R, Chopra S, Engineer R, Laskar S, Murthy V, Gupta T, Agarwal JP (2022). Impact of the first Wave of COVID-19 pandemic on radiotherapy practice at Tata Memorial Centre, Mumbai: A longitudinal cohort study. JCO Global Oncology.

Book Chapter
Kumar S, Gupta S, Maurya AP, Singh R, Nigam S. (2022). Hormonal and Targeted Treatments in Breast Cancer. In: Sharma, SC, Mazumdar, A, Kaushik R. (Eds.) Breast Cancer. Springer, Singapore. Pp. 443–463.

Sarika Tilwani. 2022. The role of 14-3-3ε in regulating development of the epidermis. (HBNI No.: LIFE09201504016) (Guide: Dr. Sorab N Dalal)

Site of the Week

CSDB (Carbohydrate Structure Database) contains manually curated natural carbohydrate structures, taxonomy, bibliography, NMR, and other data from literature.

desktop Image
Interesting Reads

Bal E, Kumar M, Hadigol M, Holmes Am Hilton L, Loh J, Dreval K, Wong J, Vlasevska S, Corinaldesi C, Soni RK, Basso K, Morin R, Khiabanian L, Dalla- Favera R. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature, 2022.

Legends of Science
Nitya Anand Nitya Anand

Nitya Anand earned his Ph.D. from the University Department of Chemical Technology, Mumbai in 1948. He received his second Ph.D. from St. John's College at Cambridge University in 1950. His important research was the demonstration of immunomodulators like MDP's role in controlling infectious diseases and enhancing the effect of chemotherapy. Discovering new drugs such as Centchroman, Centbutindole, a neuroleptic, and Centbucridine, a local anesthetic, were his significant contributions. Dr. Nitya Anand is a Fellow of the National Academy of Sciences, Allahabad; Indian Academy of Sciences, Bengaluru; and President of the Indian Pharmaceutical Congress. He was the recipient of the Padma Shri Award in 2012.

Akhil Chandra Banerjea Akhil Chandra Banerjea

Akhil Chandra Banerjea obtained his Ph.D. from the National Institute of Virology, Pune, in 1983. He worked on the effect of lentiviral vectors, stem cells, catalytic nucleic acids, and siRNA for developing gene therapy against HIV/AIDS and studying host or viral genes in understanding HIV/AIDS pathogenesis. He is an elected fellow of the National Academy of Sciences and the Indian National Science Academy. The DBT of the Government of India awarded him the National Bioscience Award for Career development in 2001. He is also elected fellow of the National Academy of Sciences, India, and the Indian National Science Academy.

Upcoming Events
19th International Congress of Developmental Biology

16-22 October, 2022

At Algarve, Portugal

India Research Management Initiative (IRMI) Annual Conference 2022

31 October-04 November, 2022


Cell Bio 2022

03-07 December, 2022

At Washington, DC

Do You Know?

In 2004, Azacitidine, an inhibitor of DNA methylation and a pioneering epigenetic therapy, became the first drug to gain US Food and Drug Administration (FDA) approval for the treatment of myelodysplastic syndrome.

back Image
Cancer News
Researchers create single-cell framework to potentially enhance CAR T-cell therapy

06 July 2022, MedicalXpress

The methodological framework the scientists created serves as a template to improve other CAR T–cell therapies by providing a guide to navigate the complexities of these immunotherapies...

Algae-based microrobots fight cancer

07 July 2022, Science News

Biohybrid microrobots consist of both living and synthetic components. While the “living part” of the robot usually provides mobility and transport, scientists can add extra functionalities to carry out specific functions, such as the release of a drug inside the body to treat cancerous tissue...

IIT Madras AI tool maps cancer-causing genes

07 July 2022, Indian Express

IIT Madras researchers have built AI prediction models for three different types of cancer, including breast Invasive carcinoma, colon adenocarcinoma and lung adenocarcinoma...

� 2022 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)